Shanghai Shyndec Pharmaceutical Co (SHSE:600420) Total Liabilities : ¥4,873 Mil (As of Sep. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Shanghai Shyndec Pharmaceutical Co Total Liabilities?

Shanghai Shyndec Pharmaceutical Co's Total Liabilities for the quarter that ended in Sep. 2024 was ¥4,873 Mil.

Shanghai Shyndec Pharmaceutical Co's quarterly Total Liabilities declined from Mar. 2024 (¥5,087.91 Mil) to Jun. 2024 (¥4,880.90 Mil) and declined from Jun. 2024 (¥4,880.90 Mil) to Sep. 2024 (¥4,873.12 Mil).

Shanghai Shyndec Pharmaceutical Co's annual Total Liabilities declined from Dec. 2021 (¥8,700.10 Mil) to Dec. 2022 (¥7,477.62 Mil) and declined from Dec. 2022 (¥7,477.62 Mil) to Dec. 2023 (¥5,014.07 Mil).

Shanghai Shyndec Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Shanghai Shyndec Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Shyndec Pharmaceutical Co Total Liabilities Chart

Shanghai Shyndec Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

8,435.27

8,547.85

8,700.10

7,477.62

5,014.07

Shanghai Shyndec Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															4,854.29	5,014.07	5,087.91	4,880.90	4,873.12

Shanghai Shyndec Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shanghai Shyndec Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3779.675	+	(1088.923	+	145.471
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	5,014

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	19352.282	-	14338.214
	=	5,014

Shanghai Shyndec Pharmaceutical Co's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4618.226	+	(49.903	+	204.986
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	4,873

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	20066.164	-	15193.049
	=	4,873

Shanghai Shyndec Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shanghai Shyndec Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Shyndec Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Shyndec Pharmaceutical Co Ltd (SHSE:600420) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

No.1320 Beijinxi Road, Shanghai, CHN, 200040

Website

http://www.shyndec.com

Shanghai Shyndec Pharmaceutical Co Ltd engages in the research, development, production, and sale of pharmaceutical preparations, biological pharmaceuticals, chemical raw materials, and Chinese medicine formulations in China and internationally. It provides biological and chemical raw material medicines, microbial fermentation products and tablets, capsules, granules, injections, suspensions, and suppositories, as well as ointments, including product formulations.

Executives

Li Hao	senior management
Ni Feng	Director
Li Xian Lin	senior management
Hao Chao Feng	senior management
Lian Wan Yong	Director
Han Yan Lin	Director
Yang Wen Ming	Supervisors
Feng Ming	Director

Shanghai Shyndec Pharmaceutical Co Headlines

No Headlines